FAKTOR-OPTIONSSCHEIN - MORPHOSYS Share Price

Certificat

DE000SR8VK38

Delayed Deutsche Boerse AG 06:01:04 10/05/2024 pm IST
3.51 EUR 0.00% Intraday chart for FAKTOR-OPTIONSSCHEIN - MORPHOSYS
Current month-1.40%
1 month+0.57%
Date Price Change Volume
10/24/10 3.51 0.00% 0
09/24/09 3.51 0.00% 0
08/24/08 3.51 +0.29% 0
07/24/07 3.5 0.00% 0
06/24/06 3.5 0.00% 0

Delayed Quote Deutsche Boerse AG

Last update May 10, 2024 at 06:01 pm IST

More quotes

Static data

Product typeExotische Produkte
Buy / SellCALL
Underlying MORPHOSYS AG
IssuerLogo Issuer Société Générale Société Générale
WKN SR8VK3
ISINDE000SR8VK38
Date issued 28/05/2020
Strike 117.9
Maturity Unlimited
Parity 1 : 1
Emission price 10.03
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 43.92
Lowest since issue 3.44

Company Profile

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Sector
-
More about the company

Ratings for MorphoSys AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: MorphoSys AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
67 EUR
Average target price
58.71 EUR
Spread / Average Target
-12.37%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW